Login or sign up
For business

Kantum Bio

3.9Β· 11 reviews
Average ratingAverage
3.9/ 5

Based on 11 reviews

527%
436%
336%
20%
10%
Ask AI

Ask Trustburn about Kantum Bio

Based on 11 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Joseph Flutie
Reviews 1

I recently purchased a product from Kantum Bio and I must say, I am quite impressed. The quality of their products is outstanding and the prices are very reasonable. I have been using their products for a few weeks now and I have noticed a significant improvement in my overall health. I would highly recommend Kantum Bio to anyone looking for high-quality health supplements.

Kris Merkel
Reviews 1

I have been using Kantum Bio products for a few months now and I am really impressed. The quality is exceptional and the prices are unbeatable. I have noticed a significant improvement in my overall well-being since I started using their products. Highly recommend!

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website β€” a simple way to convert your visitors into customers.

Get the widget for your site →

About Kantum Bio

Kantum is developing a specific AKI therapy to help critical care clinicians prevent hundreds of thousands of deaths from AKI. This targeted therapy will be supported by development of a novel diagnostic test for AKI.

Kantum Bio is developing two programs in parallel: (1) Selective receptor antagonist-based therapeutics for AKI and (2) a UDP-G diagnostic test. Kantum’s lead therapeutic development candidate, KB-1801, will be developed for the prophylaxis and treatment of AKI secondary to cardiovascular intervention. Furthermore, KB-1801 has potential in cardiovascular accidents and other conditions associated with AKI in the ICU (e.g. sepsis, polytrauma, nephrotoxicity). The UDP-G diagnostic test will enable early diagnosis of patients at risk for AKI and may be leveraged to select patients and guide their treatment in clinical studies and, ultimately, in clinical practice.